Zobrazeno 1 - 10 of 62 pro vyhledávání: '"C. L. Van Der Poel"'
1
Survival after transfusion in the Netherlands
Autor: C. L. Van Der Poel, Gouke J. Bonsel, Mart P. Janssen, W. P. Schaasberg, B. van Hout, B. A. Borkent-Raven
Publikováno v: Vox Sanguinis. 100:196-203
Background Cost-effectiveness analyses of blood safety interventions require estimates of the life expectancy after blood product transfusion. These are best derived from survival after blood transfusion, per age group and blood component type. Study
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::66f883e19baee5687eba02d8e056c194
https://doi.org/10.1111/j.1423-0410.2010.01378.x
Zobrazit plný text záznamu
2
The PROTON study: profiles of blood product transfusion recipients in the Netherlands
Autor: Mart P. Janssen, B van Hout, Gouke J. Bonsel, B. A. Borkent-Raven, C. L. Van Der Poel, W. P. Schaasberg
Publikováno v: Vox Sanguinis. 99:54-64
Background Transfusion recipient data are needed for correct estimation of cost-effectiveness in terms of recipient outcomes after transfusion. Also, such data are essential for monitoring blood use, estimation of future blood use and benchmarking. S
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::436aa447caf86b25f0da7b327a6397a3
https://doi.org/10.1111/j.1423-0410.2010.01312.x
Zobrazit plný text záznamu
3
Monitoring viral incidence rates: tools for the implementation of European Union regulations
Autor: Eric Cator, B van Hout, Gouke J. Bonsel, C. L. Van Der Poel, W. P. Schaasberg, Mart P. Janssen
Publikováno v: Vox sanguinis, 96(4), 298-308. Wiley-Blackwell
Vox Sanguinis, 96(4), 298-308. Wiley-Blackwell Publishing Ltd
BACKGROUND AND OBJECTIVES: European legislation requires manufacturers of plasma products to report epidemiological data on human immunodeficiency virus, hepatitis B virus and hepatitis C virus in donor populations. The incidence rates of such infect
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ac3b7956ba151ee3790e98cc561da5a
https://doi.org/10.1111/j.1423-0410.2009.01166.x
Zobrazit plný text záznamu
4
Cost-effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands
Autor: G.A. de Wit, C. L. Van Der Poel, Gouke J. Bonsel, Mart P. Janssen, B. A. Borkent-Raven, B van Hout
Publikováno v: Transfusion, 49(2), 311-319. Wiley-Blackwell
Background To further reduce the risk of hepatitis B virus (HBV) transmission by blood transfusion, nucleic acid testing (NAT) can be employed. The aim of this study is to estimate the incremental cost-effectiveness ratio (ICER) in the Netherlands of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a5b1b2de154bac04f3ae6edcbe1838
https://doi.org/10.1111/j.1537-2995.2008.01968.x
Zobrazit plný text záznamu
7
Paying for blood donations: still a risk?
Autor: E. Seifried, W. P. Schaasberg, C. L. Van Der Poel
Publikováno v: Vox Sanguinis. 83:285-293
It is presently disputed whether studies indicating a higher risk of infectious diseases among paid blood donors are lessons of the past, or still hold relevance. Comparative studies published between 1968 and 2001 were assessed for a possible trend
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bd53d681438c9d379689e9ec18535b50
https://doi.org/10.1046/j.1423-0410.2002.00239.x
Zobrazit plný text záznamu
8
Validation of the NucliSens Extractor in combination with the hepatitis C virus Cobas Amplicor 2.0 assay in four laboratories in the Netherlands utilizing nucleic acid amplification technology for blood screening
Autor: M. H. J. Molijn, C. L. Van Der Poel, H. T. M. Cuijpers, A. P. W. Peeters, P. N. Lelie, H. J. Bos
Publikováno v: Vox Sanguinis. 81:12-20
Background and objectives Since July 1 1999, four laboratories in the Netherlands have been routinely screening plasma minipools for the release of labile blood components utilizing hepatitis C virus nucleic acid amplification technology (HCV NAT). T
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2c5af24a50e394f352cd0ae2b897d4a8
https://doi.org/10.1046/j.1423-0410.2001.00055.x
Zobrazit plný text záznamu
9
Look-Back of Anti-HCV ELISA-Positive, HCV-RNA PCR-Negative Donors and Recipients of Their Blood Products
Autor: E. Scholten, L. C. M. Kremer, Hans L. Zaaijer, P. N. Lelie, C. L. Van Der Poel, H. W. Reesink, H. Vrielink, H. T. M. Cuypers, M. H. J. Van Oers
Publikováno v: Vox sanguinis, 72(2), 67-70. Wiley-Blackwell
Background and objectives: To establish the infectivity of anti-HCV ELISA-positive, but cDNA-PCR-negative blood components transfused before the introduction of routine anti-HCV blood donor screening, we enrolled recipients of such blood products in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::299d50602c8e20a54a5eee7c850753e2
https://doi.org/10.1046/j.1423-0410.1997.7220067.x
Zobrazit plný text záznamu
10
Evaluation of a New HTLV-I/II Polymerase Chain Reaction
Autor: H. Vrielink, H. W. Reesink, C. L. Van Der Poel, C. Winkel, Hans L. Zaaijer, P. N. Lelie, M. Woerdeman, H. T. M. Cuypers
Publikováno v: Vox sanguinis, 72(3), 144-147. Wiley-Blackwell
AIM: Evaluation of a qualitative HTLV-I/II DNA polymerase chain reaction (PCR) test for the detection of HTLV-I/II DNA (Roche Diagnostic Systems, Branchburg, N.J., USA) in various panels. METHODS: The panels consisted of fresh EDTA blood samples from
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b0f39796a3afb1294b720f70c8d7844
https://doi.org/10.1159/000461981
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje